Bellevue Group’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.4M Sell
52,518
-17,127
-25% -$5.63M 0.37% 56
2025
Q4
$24.4M Sell
69,645
-35,326
-34% -$11.9M 0.46% 45
2025
Q3
$33.9M Buy
104,971
+22,918
+28% +$7.13M 0.7% 35
2025
Q2
$31.9M Buy
82,053
+41,995
+105% +$16.9M 0.7% 36
2025
Q1
$17.4M Buy
40,058
+1,715
+4% +$688K 0.39% 55
2024
Q4
$14.1M Sell
38,343
-50,985
-57% -$21.3M 0.27% 71
2024
Q3
$46.5M Sell
89,328
-12,221
-12% -$6.53M 0.75% 36
2024
Q2
$55M Buy
101,549
+2,937
+3% +$1.55M 0.89% 27
2024
Q1
$51.1M Sell
98,612
-9,176
-9% -$4.56M 0.78% 35
2023
Q4
$50.8M Sell
107,788
-66,099
-38% -$30.6M 0.78% 40
2023
Q3
$75.7M Buy
173,887
+71,434
+70% +$32.4M 1.22% 22
2023
Q2
$45.5M Buy
102,453
+9,483
+10% +$4.37M 0.65% 51
2023
Q1
$42.7M Sell
92,970
-56,451
-38% -$26.9M 0.62% 51
2022
Q4
$76.6M Sell
149,421
-53,071
-26% -$26.9M 1.02% 30
2022
Q3
$92M Sell
202,492
-6,008
-3% -$2.87M 1.32% 23
2022
Q2
$101M Sell
208,500
-203,137
-49% -$100M 1.42% 15
2022
Q1
$202M Sell
411,637
-43,657
-10% -$20M 2.35% 8
2021
Q4
$211M Sell
455,294
-19,916
-4% -$8.38M 2.18% 10
2021
Q3
$177M Buy
475,210
+9,234
+2% +$3.51M 1.8% 13
2021
Q2
$178M Buy
465,976
+80,428
+21% +$30.7M 1.74% 13
2021
Q1
$138M Buy
385,548
+49,755
+15% +$16M 1.46% 16
2020
Q4
$108M Sell
335,793
-13,330
-4% -$4.09M 1.23% 26
2020
Q3
$93.8M Buy
349,123
+39,098
+13% +$10.5M 1.3% 21
2020
Q2
$81.5M Sell
310,025
-55,578
-15% -$14.8M 1.15% 24
2020
Q1
$83M Buy
365,603
+40,429
+12% +$11M 1.61% 16
2019
Q4
$98.2M Buy
325,174
+19,068
+6% +$5.25M 1.56% 15
2019
Q3
$73.5M Sell
306,106
-54,633
-15% -$15M 1.37% 20
2019
Q2
$102M Buy
360,739
+105,722
+41% +$28.9M 1.74% 14
2019
Q1
$73.2M Buy
255,017
+22,357
+10% +$6.47M 4.03% 6
2018
Q4
$61.1M Buy
232,660
+8,472
+4% +$2.33M 4.02% 6
2018
Q3
$61.4M Buy
224,188
+10,661
+5% +$2.77M 3.9% 1
2018
Q2
$50.8M Buy
213,527
+32,284
+18% +$7.48M 4.33% 1
2018
Q1
$39.8M Hold
181,243
3.94% 2
2017
Q4
$40.8M Buy
181,243
+10,100
+6% +$2.15M 4.26% 2
2017
Q3
$32.5M Buy
171,143
+47,796
+39% +$9.1M 3.4% 6
2017
Q2
$23.2M Buy
123,347
+12,887
+12% +$2.32M 2.74% 5
2017
Q1
$18.3M Buy
110,460
+89,860
+436% +$14.3M 2.43% 8
2016
Q4
$2.96M Hold
20,600
0.61% 47
2016
Q3
$2.58M Buy
20,600
+6,600
+47% +$852K 0.47% 59
2016
Q2
$1.84M Sell
14,000
-16,000
-53% -$2.19M 0.35% 75
2016
Q1
$4.17M Buy
+30,000
New +$4.01M 0.76% 46

Other funds holding ELV

Bellevue Group's ELV Position: Q1 2026 in Review

Bellevue Group reduced its Elevance Health (ELV) stake by 25% in Q1 2026, selling an estimated $5.63M and leaving 52,518 shares worth $15.4M. The position accounts for 0.37% of the portfolio, ranked #56.

Bellevue Group first reported a position in ELV in Q1 2016 and has held it in 41 quarters since. The position peaked at $211M in Q4 2021. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Bellevue Group held 52,518 shares of Elevance Health worth $15.4M as of Q1 2026.
  • Bellevue Group sold 17,127 Elevance Health shares in Q1 2026, an estimated $5.63M.
  • Elevance Health made up 0.37% of Bellevue Group's portfolio in Q1 2026, its #56 holding.
  • Bellevue Group first reported a position in Elevance Health in Q1 2016 and has held it in 41 quarters since.
  • Bellevue Group's Elevance Health position peaked at $211M in Q4 2021.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.